Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-18

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic.

ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising.

The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017.

Few clinical data have been published so far concerning the French population.

The investigators would like to build a database so that the investigators can publish our results and share our experience.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical 0.01% Atropine for the Control of Fast Progressing Myopia

NCT04173780

Myopia Progressing Childhood

TERMINATED PHASE2/PHASE3

Low-dose Atropine for Myopia Control in Children

NCT03865160

Myopia, Progressive

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

NCT07095894

Myopia

NOT_YET_RECRUITING PHASE3

Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia

NCT05448989

Myopia

UNKNOWN PHASE4

Low Concentration Atropine in the Prevention of Myopia in Children.

NCT05939882

Myopia, Progressive

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with active myopia treated with ATROPINE eye drops

data collection

Intervention Type OTHER

* Demographic data: age, sex
* Ophthalmological history: refraction of parents, previous refractions
* Ophthalmological data at each examination: intra-ocular pression, objective refraction after "fog", cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics
* Potential undesirable events (halos, photophobia...)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

data collection

* Demographic data: age, sex
* Ophthalmological history: refraction of parents, previous refractions
* Ophthalmological data at each examination: intra-ocular pression, objective refraction after "fog", cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics
* Potential undesirable events (halos, photophobia...)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children with active myopia treated with ATROPINE 0.01% eye drops
* patient affiliated with a social security organization
* agreement of both parents